structural maintenance of chromosomes 1BGenealiases: SMC1BETA · SMC1L2
Q-omics provides the consensus-scored SMC1B profile across patient tissues and cancer cell-line models. SMC1B expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, SMC1B is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, SMC1B RNA expression shows 16,875 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and KIRC as cancer lineages where SMC1B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SMC1B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SMC1B survival associations across molecular data types. SMC1B RNA expression shows survival associations in the most cancer types (27), followed by mutation status (5) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SMC1B RNA expression–survival associations across cancer types. High SMC1B expression shows unfavorable associations in ACC, KIRC, BRCA and COAD, but favorable associations in SCLC and CESC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for SMC1B RNA expression.
This table summarizes SMC1B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for SMC1B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SMC1B shows higher tumor expression in KIRC, HNSC, BLCA, LUAD, LIHC and LUSC. The KIRC box plot shows higher SMC1B RNA expression in tumor versus normal tissue (log2 FC = +0.166, t-test p < 0.001).
This table shows molecular features associated with SMC1B in patient tissues and cancer cell lines. In patient samples, SMC1B shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, SMC1B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and LARGE_INTESTINE.
